Q3 2024 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2024-11-14 · accession 0000950123-24-011756
$591.9M
Reported value
6
Positions
2024-09-30
Period end
The Brief · Flagship Pioneering, LLC · Q3 2024
AI · grounded in 13F
Flagship Pioneering, LLC reported no changes to its 13F holdings for 2024-09-30 relative to 2024-06-30.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $309.6M | 52.3% | 4,632,149 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $118.0M | 19.9% | 12,674,120 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $104.0M | 17.6% | 25,001,856 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $35.7M | 6.02% | 29,225,579 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $21.9M | 3.70% | 23,117,045 | Common | SHARED |
| 87184Q206 | SYRS | Syros Pharmaceuticals Inc | $2.8M | 0.47% | 1,293,849 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.